Heart Failure with Preserved Ejection Fraction (HFpEF): Pathophysiology vs Outcomes Are We Narrowing the Gap?
Industry Webcast Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE Credit
Heart failure with preserved ejection fraction (HFpEF) is a complex disease with pathophysiological heterogeneity, whose treatment is primarily focused on management of symptoms vs treatment of the underlying disease. This talk will highlight some of the multiple pathways being explored in the attempt to bridge the gap between managing comorbidities/symptoms and treating the disease itself.
This content is developed exclusively by or on behalf of the industry sponsor; it is not reviewed or associated with Pri-Med and Pri-Med does not endorse or sanction any third-party content.
